Advisortrust Partners’s Cue Biopharma CUE Stock Holding History

Advisortrust Partners’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,667	Closed	-$11.5K	–	217
2026 Q1	$11.5K	Buy	+1,667	New	+$15.6K	﹤0.01%	237

Other funds holding CUE

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $322M AUM

Advisortrust Partners's CUE Position: Q2 2026 in Review

Advisortrust Partners sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 1,667 shares — an estimated $11.5K sold.

Advisortrust Partners first reported a position in CUE in Q1 2026 and held it in 1 quarter. The position peaked at $11.5K in Q1 2026. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

Advisortrust Partners reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
Advisortrust Partners sold 1,667 Cue Biopharma shares in Q2 2026, an estimated $11.5K.
Advisortrust Partners first reported a position in Cue Biopharma in Q1 2026 and held it in 1 quarter.
Advisortrust Partners's Cue Biopharma position peaked at $11.5K in Q1 2026.
49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Advisortrust Partners's 13F filing for Q2 2026, filed 10 Aug 2026.